AMYLYX PHARMACEUTICALS INC (AMLX) Institutional Ownership

None of the superinvestors we track currently report AMYLYX PHARMACEUTICALS INC (AMLX) in their latest SEC Form 13F filings.

13F filings cover institutional equity holdings and are reported quarterly with a delay. This stock may still have insider Form 4 activity or appear in future filings.

When tracked funds report positions in AMYLYX PHARMACEUTICALS INC (AMLX), this page will show institutional ownership trends, hedge fund exposure, portfolio concentration, historical 13F filings, and estimated holding performance.

Institutional Ownership Trend

Portfolio quarterInstitutional holdersTotal reported valueTotal shares
Q4 20251$2,325,400192,500
Q3 20251$270,44119,900
Q2 20251$2,539,642396,200
Q1 20251$1,823,454515,100
Q4 20241$1,755,432464,400
Q3 20241$880,632271,800
Q2 20241$1,541,827811,488
Q1 20241$2,001704,600
Q4 20232$43,609,8593,033,843
Q3 20232$54,247,1303,112,655
Q2 20231$63,902,3112,962,555
Q1 20231$86,921,3642,962,555
AMLX Institutional Ownership and 13F Activity | InsiderSet